Flag Ship Acquisition (NASDAQ:ETHZ) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Flag Ship Acquisition's stock has been given a "sell (D-)" rating by Weiss Ratings, indicating a negative outlook for investors.
• Wall Street Zen further downgraded the stock to a "strong sell" rating on August 30, contributing to a consensus rating of "Sell".
• The stock is currently trading at $2.32, with a twelve-month range of $0.66 to $17.75, reflecting significant volatility.

Flag Ship Acquisition (NASDAQ:ETHZ - Get Free Report)'s stock had its "sell (d-)" rating reiterated by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded Flag Ship Acquisition to a "strong sell" rating in a report on Saturday, August 30th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of "Sell".

Flag Ship Acquisition Stock Down 0.4%

Shares of NASDAQ ETHZ opened at $2.32 on Wednesday. Flag Ship Acquisition has a twelve month low of $0.66 and a twelve month high of $17.75. The company has a market capitalization of $381.48 million, a PE ratio of -0.15 and a beta of 0.38.

Flag Ship Acquisition Company Profile

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.